Ticker > Company >

Fredun Pharma share price

Fredun Pharmaceuticals Ltd.

BSE: 539730 SECTOR: Pharmaceuticals & Drugs  17.28 K   42   4

1245.00
-33.70 (-2.64%)
BSE: 10 Sep 04:01 PM

Price Summary

Today's High

₹ 1275

Today's Low

₹ 1214.8

52 Week High

₹ 1340

52 Week Low

₹ 635

FinStar

Ownership Stable
Ownership strength is slightly missing the benchmark.
ValuationFair
The stock’s market price justifies its intrinsic value.
EfficiencyOptimal
The company could improve upon its asset employment.
FinancialsAverage
The company could improve upon its asset employment.
*It is just an analytical rating of the company and not an investment advice.

Company Essentials

Market Cap

587.85 Cr.

Enterprise Value

692.01 Cr.

No. of Shares

0.47 Cr.

P/E

25.07

P/B

3.97

Face Value

₹ 10

Div. Yield

0.06 %

Book Value (TTM)

₹  313.8

CASH

1.35 Cr.

DEBT

105.51 Cr.

Promoter Holding

48.93 %

EPS (TTM)

₹  49.65

Sales Growth

26.75%

ROE

15.03 %

ROCE

17.13%

Profit Growth

44.57 %

* Total debt includes long term borrowing, short term borrowing plus current maturities of long-term borrowing
* Ratios are based on latest Audited Financial Result.

Your Added Ratios

Please login to Add & View your own added ratios.

Login

Brands

These are the brands of Fredun Pharmaceuticals Ltd.

MAMALAIT GRANULES FREDCAL BIRD AND BEAUTY PURI5 FREPREIMECAL FREOSSITONE GRANULES FREOSSIPOWER

Price Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

 

Volume Chart 1d 1w 1m 3m 6m 1Yr 3Yr 5Yr

* Prices are based on daily market changes.
* The chart is based on the standalone earnings of the company. * Negative values and values more than 1000x in PE chart is considered 0.

Peer Comparison

View Full Peer Comparison
* The Peers list includes companies operating in the same industry and having comparable market cap.

 Group Companies

Track the companies of Group.

Ratios

Sales Growth

1 Year26.75%
3 Year37.51%
5 Year29.12%

Profit Growth

1 Year44.57%
3 Year97.93%
5 Year28.5%

ROE%

1 Year15.03%
3 Year13.44%
5 Year9.96%

ROCE %

1 Year17.13%
3 Year15.97%
5 Year13.56%

Debt/Equity

0.88

Price to Cash Flow

-1339.97

Interest Cover Ratio

2.5716

CFO/PAT (5 Yr. Avg.)

0

Shareholding Pattern

Promoter Pledging %

Date Promoter % Pledge %
Jun 2025 48.93 0.00
Mar 2025 48.93 0.00
Dec 2024 48.93 0.00
Sep 2024 48.93 0.00
Jun 2024 49.17 0.00
Investors List
* Figures given above are % of equity capital

 Strengths

  • The company has shown a good profit growth of 97.9346018538067% for the Past 3 years.
  • The company has shown a good revenue growth of 37.510840892994% for the Past 3 years.
  • Company’s PEG ratio is 0.635795898620686.

 Limitations

  • Company has negative cash flow from operations of -0.4387.

Quarterly Result (All Figures in Cr.)

PARTICULARS Jun 2024 Sep 2024 Dec 2024 Mar 2025 Jun 2025
Net Sales 78.81 107.35 102.7 167.41 119.86
Total Expenditure 68.33 93.4 89.47 149.97 102.86
Operating Profit 10.48 13.95 13.23 17.44 16.99
Other Income 0 0 0 0 0
Interest 3.91 5.31 5.01 8.15 6.53
Depreciation 1.05 1.06 1.09 1.25 1.42
Exceptional Items 0 0 0 0 0
Profit Before Tax 5.52 7.58 7.14 8.04 9.04
Tax 1.39 3.3 1.8 0.97 2.28
Profit After Tax 4.13 4.27 5.33 7.07 6.77
Adjusted EPS (Rs) 8.79 9.05 11.29 14.98 14.33

Profit & Loss (All Figures in Cr. Adjusted EPS in Rs.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Net Sales 112.77 133.89 224.46 274.68 348.16
Total Expenditure 104.44 124.55 210.55 246.9 310.17
Operating Profit 8.33 9.35 13.91 27.78 37.98
Other Income 0.52 1.4 1.63 1.82 0.92
Interest 4.47 4.37 4.78 9.28 13.65
Depreciation 1.88 2 2.16 2.81 3.8
Exceptional Items 0 -1.16 0 0 0
Profit Before Tax 2.49 3.21 8.6 17.51 21.45
Tax 0.59 1.19 2.26 6.7 5.83
Net Profit 1.9 2.01 6.34 10.81 15.62
Adjusted EPS (Rs.) 4.77 5.05 14.29 23.84 33.25

Balance Sheet (All Figures are in Crores.)

Particulars Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Equity and Liabilities
Share Capital 3.99 3.99 4.43 4.53 4.7
Total Reserves 37.33 39.08 63.63 91.84 116.77
Borrowings 11.5 29.11 42.04 15.44 12.8
Other N/C liabilities 2.57 2.98 3.14 5.81 6.5
Current liabilities 85.99 86.46 73.75 139.66 166.83
Total Liabilities 141.38 161.62 186.99 257.28 307.6
Assets
Net Block 30.97 30.35 32.34 38.93 46.57
Capital WIP 0 0 0 0 0
Intangible WIP 0 0 0 0 0
Investments 0 0 0 0 0
Loans & Advances 1.08 1.18 2 2.13 3.36
Other N/C Assets 0 0 0 0 0.46
Current Assets 109.32 130.08 152.65 216.21 257.2
Total Assets 141.38 161.62 186.99 257.28 307.6
* Other Non-current Liabilities include Net deferred Liabilities

Cash Flows (All Figures are in Crores.)

PARTICULARS Mar 2020 Mar 2021 Mar 2022 Mar 2023 Mar 2024
Profit from operations 2.35 2.01 8.58 17.46 21.45
Adjustment 6.03 8.65 7.82 11.7 16.77
Changes in Assets & Liabilities -19.02 -10.5 -18.77 -43.57 -38.66
Tax Paid 0 0 0 0 0
Operating Cash Flow -10.64 0.17 -2.38 -14.41 -0.44
Investing Cash Flow -1.49 -1.39 -4.14 -9.4 -7.64
Financing Cash Flow 13.73 -0.71 7.47 25.18 5.99
Net Cash Flow 1.59 -1.93 0.94 1.36 -2.08

Corporate Actions

Investors Details

PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
promoters 49.17 48.93 48.93 48.93 48.93
daulat nariman medhora 30.02 29.88 29.88 29.88 29.88
fredun nariman medhora 3.82 3.81 3.81 3.81 3.81
nariman medhora 15.32 15.24 15.24 15.24 15.24
PARTICULARS Jun 2024% Sep 2024% Dec 2024% Mar 2025% Jun 2025%
investors 50.83 51.07 51.07 51.07 51.07
arun kumar mukherjee 1.70 1.43 1.03 1.03 1.02
bank of india 1.60 1.59 1.59 1.59 1.59
harsha venkatesh - - - 1.06 1.06
llp 0.49 0.48 0.41 0.28 0.32
nikhil kishorchandra vora... 6.41 6.38 6.38 6.38 6.38

Annual Reports

Title Link
Title Link
Annual Report 2021
Annual Report 2020
Annual Report 2019
Annual Report 2018
Annual Report 2017
Annual Report 2017

Ratings & Research Reports

TYPE AGENCY Link
TYPE AGENCY Link
 No Credit reports exist for this company.Report us
TYPE AGENCY Link
TYPE AGENCY Link
 No Research reports exist for this company.Report us

Concalls & Presentations

TYPE QUARTER Link
TYPE QUARTER Link
 Currently we do not have any Concall related to this company.Report us
TYPE QUARTER Link
TYPE QUARTER Link
Presentation Q3FY23
Presentation Q3FY22

Company News

Fredun Pharma - Quaterly Results 30 Jul, 6:54 PM Fredun Pharma - Quaterly Results 30 Jul, 6:54 PM Fredun Pharma - Quaterly Results 30 Jul, 6:54 PM Fredun Pharmaceuticals’ arm acquires controlling interest in One Pet Stop 30 Jun, 3:29 PM Fredun Pharma - Quaterly Results 31 May, 7:58 PM Fredun Pharmaceuticals informs about board meeting 22 May, 5:26 PM Fredun Pharmaceuticals secures tender from TNMSC for supply of generic medicines 10 Apr, 2:35 PM Fredun Pharmaceutical informs about press release 3 Apr, 3:13 PM Fredun Pharmaceuticals forays into large animal veterinary segment 12 Mar, 9:44 AM Fredun Pharma - Quaterly Results 4 Feb, 7:59 PM Fredun Pharma - Quaterly Results 4 Feb, 7:59 PM Fredun Pharmaceuticals installs second Italian Tube Filling Machine at production facility 3 Feb, 3:08 PM Fredun Pharmaceuticals launches India’s first dedicated Pet Diagnostic Center 9 Jan, 3:58 PM Fredun Pharma - Quaterly Results 26 Oct, 9:40 PM Fredun Pharma - Quaterly Results 29 Jul, 7:32 PM Fredun Pharma - Quaterly Results 29 Jul, 7:32 PM Fredun Pharma - Quaterly Results 7 May, 10:10 PM Fredun Pharma - Quaterly Results 7 May, 10:10 PM Fredun Pharma - Quaterly Results 14 Feb, 7:24 PM Fredun Pharma - Quaterly Results 14 Feb, 7:24 PM Fredun Pharmaceuticals informs about press release 12 Feb, 1:29 PM Fredun Pharmaceuticals gets orders worth Rs 28 crore from SEA countries 12 Feb, 12:41 PM Fredun Pharmaceuticals informs about voting results of EGM 19 Jan, 5:16 PM Fredun Pharmaceuticals informs about loss of original share certificates 17 Jan, 3:24 PM Fredun Pharmaceuticals informs about board meeting 9 Dec, 2:37 PM Fredun Pharmaceuticals informs about outcome of board meeting 2 Aug, 5:10 PM Fredun Pharmaceuticals informs about press release 21 Jul, 5:08 PM Fredun Pharma - Quaterly Results 19 Jul, 6:15 PM Fredun Pharma - Quaterly Results 19 Jul, 6:15 PM Fredun Pharma - Quaterly Results 19 Jul, 6:15 PM Fredun Pharmaceuticals informs about outcome of board meeting 25 May, 9:46 AM Fredun Pharmaceuticals informs about revised outcome of board meeting 3 May, 3:12 PM Fredun Pharmaceuticals informs about outcome of board meeting 28 Jan, 11:50 AM Fredun Pharma - Quaterly Results 27 Jan, 8:10 PM Fredun Pharma - Quaterly Results 27 Jan, 8:10 PM Fredun Pharmaceuticals informs about certificate 3 Jan, 3:07 PM Fredun Pharmaceuticals informs about change in registered office address 13 Dec, 3:07 PM Fredun Pharmaceuticals informs about press release 28 Nov, 5:17 PM Fredun Pharmaceuticals bags two contracts for Pharma and DC Granules 28 Nov, 4:42 PM Fredun Pharma - Quaterly Results 10 Nov, 7:43 PM Fredun Pharma - Quaterly Results 10 Nov, 7:43 PM Fredun Pharma - Quaterly Results 16 May, 7:00 PM Fredun Pharma - Quaterly Results 16 May, 7:00 PM Fredun Pharmaceuticals informs about board meeting 9 May, 10:13 AM Fredun Pharmaceuticals gets nod to manufacture Xenografts 15 Mar, 10:11 AM Fredun Pharma - Quaterly Results 6 Nov, 4:30 PM Fredun Pharma - Quaterly Results 6 Nov, 4:30 PM Fredun Pharma - Quaterly Results 6 Nov, 4:30 PM Fredun Pharmaceuticals informs about confirmation certificate 4 Oct, 3:40 PM Fredun Pharmaceuticals informs about issue of securities 15 Sep, 5:18 PM

Fredun Pharma Stock Price Analysis and Quick Research Report. Is Fredun Pharma an attractive stock to invest in?

Stock investing requires careful analysis of financial data to determine a company's true net worth. This is generally done by examining the company's profit and loss account, balance sheet and cash flow statement, which can be time-consuming and cumbersome.

Examining a company's financial ratios is an easier way to determine its performance, which can help to make sense of the overwhelming amount of information in its financial statements. 

Here are a few indispensable ratios that should be a part of every investor’s research process, or, in simpler words, how to analyse Fredun Pharma. 

  • PE ratio: Price to Earnings ratio, which indicates how much an investor is willing to pay for a share for every rupee of earnings. A general rule of thumb is that shares trading at a low P/E are undervalued (it depends on other factors too). Fredun Pharma has a PE ratio of 25.1349391766696 which is high and comparatively overvalued.

  • Return on Assets (ROA): Return on Assets measures how effectively a company can earn a return on its investment in assets. In other words, ROA shows how efficiently a company can convert the money used to purchase assets into net income or profits. Fredun Pharma has ROA of 5.5316% which is a bad sign for future performance. (Higher values are always desirable.)

  • Current ratio: The current ratio measures a company's ability to pay its short-term liabilities with its short-term assets. A higher current ratio is desirable so that the company could be stable to unexpected bumps in business and economy. Fredun Pharma has a Current ratio of 1.5417.

  • Return on equity: ROE measures the ability of a firm to generate profits from its shareholders' investments in the company. In other words, the return on equity ratio shows how much profit each rupee of common stockholders’ equity generates. Fredun Pharma has a ROE of 15.0262%. (Higher is better)

  • Debt to equity ratio: It is a good metric to check out the capital structure along with its performance. Fredun Pharma has a Debt to Equity ratio of 0.88 which means that the company has low proportion of debt in its capital.

  • Sales growth: Fredun Pharma has reported revenue growth of 26.7518% which is fair in relation to its growth and performance. 

  • Operating Margin: This will tell you about the operational efficiency of the company. The operating margin of Fredun Pharma for the current financial year is 10.9095572619416%.

  • Dividend Yield: It tells us how much dividend we will receive in relation to the price of the stock. The current year dividend for Fredun Pharma is Rs 0.7 and the yield is 0.0562%.

  • Earnings Per Share: It tells us how much profit is allocated to to each outstanding share of a common stock. The latest EPS of Fredun Pharma is Rs 49.652. The higher the EPS, the better it is for investors. 

One can find all the Financial Ratios of Fredun Pharma in Ticker for free. Also, one can get the intrinsic value of Fredun Pharma by using Valuation Calculators, which are available with a Finology ONE subscription. 

Fredun Pharma FAQs

Q1. What is Fredun Pharma share price today?
Ans: The current share price of Fredun Pharma is Rs 1248.

Q2. What is the market capitalisation of Fredun Pharma?
Ans: Fredun Pharma has a market capitalisation of Rs 589.2634176 Cr., calculated based on its latest share price.

Q3. What are the P/E and P/B ratios of Fredun Pharma?
Ans: The PE ratio of Fredun Pharma is 25.1349391766696 and the P/B ratio of Fredun Pharma is 3.97705798410324, showing how the stock is valued against its earnings and book value.

Q4. What is the 52-week high and low of Fredun Pharma share?
Ans: The 52-week high share price of Fredun Pharma is Rs 1340, and the 52-week low share price of Fredun Pharma is Rs 635.

Q5. Does Fredun Pharma pay dividends?
Ans: Currently, Fredun Pharma pays dividends. Dividend yield of Fredun Pharma is around 0.0562%.

Q6. What are the face value and book value of Fredun Pharma shares?
Ans: The face value of Fredun Pharma shares is Rs 10, while the book value per share of Fredun Pharma is around Rs 313.7998. Face value is the nominal value set by the company, whereas book value reflects its accounting worth.

Q7. What is the debt of Fredun Pharma?
Ans: Fredun Pharma has a total debt of Rs 105.5099 Cr., which affects investor sentiment and financial stability. 

Q8. What are the ROE and ROCE of Fredun Pharma?
Ans: The ROE of Fredun Pharma is 15.0262% and ROCE of Fredun Pharma is 17.127%. ROE shows how efficiently the company is generating profit from shareholders’ equity, while the ROCE is reflects how efficiently the company uses its capital to generate returns.

Q9. Is Fredun Pharma a good buy for the long term?
Ans: The Fredun Pharma long-term outlook depends on debt levels, earnings growth, and sector trends. If it sustains profits and manages debt well, it may be considered for long-term investment.

Q10. Is Fredun Pharma undervalued or overvalued?
Ans: Based on valuation ratios like P/E, P/B, and EV/EBITDA, one can analyse whether the Fredun Pharma appears undervalued or overvalued at current levels. You can check detailed valuation metrics and peer comparisons on Finology Ticker.

Q11. How to check Fredun Pharma’s financials?
Ans: You can review Fredun Pharma’s financial statements - including balance sheet, income statement, and quarterly results - on Finology Ticker.

Last Updated on:
Brief about Fredun Pharma
X